pdufa.bio
CalendarDecisionsApprovals/yrTrial oddsLearnResearchMethodology
Home › PDUFA Calendar › ALPMY

ALPMY PDUFA Date: KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv)

FDA decision (PDUFA) target 2026-08-17 · Astellas Pharma Inc. ADR · Muscle-invasive bladder cancer (MIBC)

ALPMY run-up into the PDUFA (last ~120 days)

$16.78$13.23
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-08-17
Drug / candidateKEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv)
IndicationMuscle-invasive bladder cancer (MIBC)
CompanyAstellas Pharma Inc. ADR
Market-cap tierLarge
Cohort decision-day move (history)±1% median
ClinicalTrials.govNCT04700124 · completed

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

Track this live → price, options (expected move & IV) and the full dashboard
Opens the pdufa.bio app (private beta)

FAQ

When is the ALPMY PDUFA date?
The FDA PDUFA target date for ALPMY (Astellas Pharma Inc. ADR) is 2026-08-17 for KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv). Dates are company/FDA-sourced and can slip — verify against primary filings.
What is ALPMY's drug KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv)?
KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) is Astellas Pharma Inc. ADR's candidate under FDA review for Muscle-invasive bladder cancer (MIBC).
What typically happens to a large-cap stock into a PDUFA date?
Historically, large-cap names had a median decision-day move around ±1% (694-PDUFA cohort, 2024–26). This is historical context by market-cap tier, not a prediction for this drug.